10x Science has secured $4.8 million in seed funding to help pharmaceutical researchers interpret the flood of AI-generated molecular candidates. The startup addresses a critical gap: AI can propose drugs faster than humans can evaluate them.
Drug discovery has entered a computational paradox. Machine learning models now generate thousands of potential drug candidates in hours—far outpacing traditional screening methods. But identifying which molecules actually warrant clinical testing remains a bottleneck.
10x Science tackles this by helping researchers understand complex molecular data. The startup's platform cuts through the noise, letting pharma teams focus resources on the most promising candidates.
The $4.8 million seed round reflects investor confidence in the problem's scale. As AI models grow more powerful, the gap between discovery speed and validation only widens. Firms that can efficiently filter AI-generated compounds gain significant competitive advantage.
The pharmaceutical industry has increasingly adopted AI for drug development, reducing timelines from years to months for initial candidate identification. But converting AI predictions into viable therapies still requires human expertise and wet-lab validation.
Town, an enterprise personal AI assistant platform, is in talks to raise funding at a $1 billion valuation in a round led by Index Ventures, according to sources.
Product management platform Linear reached $100M in annual recurring revenue and conducted a $99M employee tender offer at a $2.5B valuation, doubling its valuation from $1.25B in 2025.
Flipboard is acquiring Bluesky feed-building startup Graze, integrating its ad technology and creator monetization tools into its open social web platform.
Artificial intelligence is fundamentally changing how startups operate, not just what they build. According to Floodgate co-founder Ann Miura-Ko, companies are deploying AI agents across engineering, sales, marketing, and strategy to accelerate learning and execution.